Ototoxicity of cisplatin.
Ototoxicity is one of the unwanted side effects of cisplatin treatment. The first sign of hearing loss usually appears 3-4 days after the drug administration and occurs primarily in the higher frequencies. One hundred and eighty-six women treated with a moderate dose of cisplatin (50 mg/m2 every 4 weeks) for gynaecological cancer were studied. No significant loss of hearing was detected in the speech frequency range. Since the cisplatin concentration in the inner ear is highest after a single high dose injection, systemic audiometric monitoring is advisable during cisplatin therapy with single high dose regimen.
D000818:Animals; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity*; D003051:Cochlea / Q000187:drug effects / Q000473:pathology; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D034381:Hearing Loss / Q000139:chemically induced*; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D012306:Risk
D002945:Cisplatin